Dashboard
Manage Tickers

CUE Cue Biopharma, Inc.

Nasdaq cuebiopharma.com


$ 0.79 $ 0.00 (0.63 %)    

Friday, 24-Oct-2025 15:59:52 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 0.7852
$ 0.80
$ 0.71 x 50
$ 0.83 x 5,000
$ 0.76 - $ 0.80
$ 0.54 - $ 1.99
91,925
na
60.34M
$ 1.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-03-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-21-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-16-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-09-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 03-14-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-13-2018 06-30-2018 10-Q
30 05-14-2018 03-31-2018 10-Q
31 03-29-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/09/2025 21:06:16

lucid-capital-markets-initiates-coverage-on-cue-biopharma-with-buy-rating-announces-price-target-of-4
LUCID CAPITAL MARKETS Initiates Coverage O...
08/25/2025 17:27:53

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Buy rating and announces P...

cue-biopharma-initiates-investigator-sponsored-trial-of-cue-102-for-recurrent-glioblastoma-multiforme
Cue Biopharma Initiates Investigator Spons...
08/13/2025 12:09:02

cue-biopharma-q2-eps-009-beats-014-estimate-sales-2954m-beat-2396m-estimate
Cue Biopharma Q2 EPS $(0.09) Beats $(0.14)...
08/12/2025 20:33:23

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) ...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/16/2025 21:06:00

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/16/2025 17:06:26

reported-earlier-cue-biopharma-reports-50-overall-response-rate-and-88-12-month-survival-in-cue-101-trial-for-hpv-cancers
Reported Earlier: Cue Biopharma Reports 50...
07/16/2025 16:06:52

Additional complete response (CR) observed in patient with multiple tumorsConfirmed overall response rate (ORR) of 50% in patie...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/01/2025 21:05:47

cue-biopharma-issues-update-on-its-clinical-stage-asset-cue-101-representative-of-cue-100-series-data-highlights-include-orr-of-50-in-treatment-naive-patients-with-hpv-rm-hnscc
Cue Biopharma Issues Update On Its Clinica...
07/01/2025 20:08:30

ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC12-month landmark survival of 88% and mOS of 32 monthsBOSTON, July 01...

cue-biopharma-receives-fda-pre-ind-feedback-for-lead-autoimmune-therapy-cue-401-plans-ind-filing-pending-final-studies
Cue Biopharma Receives FDA Pre-IND Feedbac...
06/24/2025 20:50:01

Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics ...

cue-biopharma-ceo-daniel-passeri-to-serve-as-interim-cfo-kerri-ann-millar-resigns-as-cfo
Cue Biopharma CEO Daniel Passeri To Serve ...
06/10/2025 20:05:08

 - SEC Filing

cue-biopharma-q1-eps-017-misses-015-estimate-sales-42100k-miss-127m-estimate
Cue Biopharma Q1 EPS $(0.17) Misses $(0.15...
05/12/2025 20:49:12

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15...

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
04/15/2025 21:05:49

reported-earlier-cue-biopharma-prices-20m-public-offering-of-common-stock-and-warrants-at-079
Reported Earlier, Cue Biopharma Prices $20...
04/15/2025 06:31:04

cue-biopharma-announces-proposed-public-offering-no-size-or-amount-disclosed
Cue Biopharma Announces Proposed Public Of...
04/14/2025 21:06:35

Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics ...

cue-biopharma-and-boehringer-ingelheim-announce-strategic-partnership-to-develop-and-commercialize-first-in-class-bispecific-t-cell-engaging-b-cell-depletion-therapy-cue-501-for-autoimmune-and-inflammatory-diseases-aiming-for-earlier-intervention-and-long-term-disease-control
Cue Biopharma And Boehringer Ingelheim Ann...
04/14/2025 21:03:20

Partnership bolsters Boehringer's autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unm...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
04/07/2025 12:08:52

citizens-capital-markets-reiterates-market-outperform-on-cue-biopharma-maintains-2-price-target
Citizens Capital Markets Reiterates Market...
04/02/2025 15:07:04

Citizens Capital Markets analyst Reni Benjamin reiterates Cue Biopharma (NASDAQ:CUE) with a Market Outperform and maintains ...

whats-going-on-with-cue-biopharma-shares-tuesday
What's Going On With Cue Biopharma Shares ...
04/01/2025 16:14:03

Cue reported 2024 fiscal-year earnings on Monday after the market closed.

cue-biopharma-fy24-eps-072-up-from-111-yoy-revenue-9287m-up-from-5490m-yoy
Cue Biopharma FY24 EPS ($0.72) Up From ($1...
03/31/2025 20:27:39

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION